Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Janice M. Reichert" Clear advanced filters

  • Monoclonal antibodies are now established as a key therapeutic modality for a range of diseases, including cancer. Reichert and Valge-Archer overview trends in the development and regulatory approval of anticancer monoclonal antibodies since 1980, with the aim of informing future research and development for this class of therapeutics.

    • Janice M. Reichert
    • Viia E. Valge-Archer
    Reviews
    Nature Reviews Drug Discovery
    Volume: 6, P: 349-356

  • Fully human monoclonal antibodies (mAbs), which have the potential to be less immunogenic than earlier humanized and chimeric mAbs, are the most rapidly growing class of mAbs in clinical development. Here, Reichert and colleagues highlight trends in the development of human mAbs, seven of which have so far gained regulatory approval.

    • Aaron L. Nelson
    • Eugen Dhimolea
    • Janice M. Reichert
    Reviews
    Nature Reviews Drug Discovery
    Volume: 9, P: 767-774

  • Most monoclonal antibodies so far have been developed for treating cancer or immune disorders, but opportunities for the development of monoclonal antibodies to target infectious diseases seem to be increasing. Reichert and Dewitz analyse trends in the development of anti-infective monoclonal antibodies and discuss factors that influence their success.

    • Janice M. Reichert
    • Matthew C. Dewitz
    Reviews
    Nature Reviews Drug Discovery
    Volume: 5, P: 191-195